Overview

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the efficacy and safety of TMC435 plus PSI-7977 (GS7977) with or without ribavirin in patients who are chronically infected with genotype 1 hepatitis C virus (HCV) and who did not respond to prior peginterferon/ribavirin therapy or are HCV treatment-naive (patients who never received treatment for HCV infection).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen R&D Ireland

Collaborator:

Gilead Sciences

Treatments:

Ribavirin
Simeprevir
Sofosbuvir